Georges Gemayel joins NPS Pharmaceuticals board
This article was originally published in Scrip
NPS Pharmaceuticals, a biopharmaceutical company developing orphan products for rare disorders, has appointed Dr Georges Gemayel to its board of directors. Dr Gemayel previously served as chair of FoldRx Pharmaceuticals, as well as president and CEO of Altus Pharmaceuticals from 2008-09. Prior to Altus, he was an executive vice-president of Genzyme.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.